Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Teriparatide Biosimilar (Beijing Genetech Pharmaceutical Co. Ltd.), 特立帕肽生物类似药(Beijing Genetech Pharmaceutical Co. Ltd.) + [1] |
Target |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (16 Jan 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis, Postmenopausal | CN | 16 Jan 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoporosis | Preclinical | CN | 26 Apr 2024 |